3 Stocks Near 52-Week Highs Worth Selling
Sep 12th 2013 6:41PM
Updated Sep 12th 2013 6:42PM
Just when you thought the broad-based S&P 500 was finally going to cool off, we're right back near an all-time record high, with seven-consecutive up days. For skeptics like me, that's an opportunity to see whether companies have earned their current valuations.
Keep in mind that some companies deserve their current valuations. Take footwear giant Nike , for example. Its share price hit a new 52-week high this week on news that it would be moving into the Dow Jones Industrial Average, requiring index funds that track the Dow to purchase Nike stock. Even more than that, in the fourth quarter, it reported that future brand orders were up 8% over the previous year. With little signs of slowing growth and a dominant, well-recognized global brand name, Nike deserves every bit of its new 52-week high.
Still, other companies might deserve a kick in the pants. Here's a look at three companies that could be worth selling.
Is this stock Finnish-ed?
I admit to being a big supporter of Nokia during its dark days, when few analysts figured it would survive, and most had written off its mobile unit for dead. In July 2012, I broke down Nokia's parts into smaller bits and surveyed their worth, determining that the share price should have been closer to $4 when it was instead trading around $2.
Since that article more than a year ago, Nokia purchased the full rights to its previously shared networking solutions joint venture with Siemens, and sold off its mobile units, comprised of its Lumia smartphones, to Microsoft for $7.2 billion. The move made sense for both parties, since Microsoft already had an operating system partnership with Nokia for the Lumia, and is desperately trying to diversify its revenue stream beyond PC operating systems, and Nokia, frankly, needed the cash! However, at nearly $6 per share, I feel Nokia's run may be coming to an end.
Let's look at it this way: On the bright side, Nokia received a gigantic cash infusion, which will support R&D for years to come, and give it some downside protection. On the other hand, although a boom is coming in networking equipment, Nokia's really not in any shape to take advantage of it. Even if it were, the 53% gain the stock has experienced since announcing the sale of its smartphone unit to Microsoft more than accounts for what strength its networking solutions unit might encounter as wireless service provider infrastructure spending trickles its way down the line.
Obviously, getting back to profitability will be a key for Nokia, and I do believe it eventually can be profitable again. Although, at 40 times next year's projected profits, I feel now is not the time to be chasing this stock higher, and would stick to the sidelines until it proves otherwise.
A spliced budget
This one is a bit of a tough call because I like the stock and its technology, but it's also a great reminder never to fall in love with a company. The company in question that's on the hot seat this week is life science tools and systems maker Illumina .
On the grand scale, Illumina offers a very intriguing business model. The company's genetic and biologic analysis tools are a smart choice for an aging baby-boomer population when it comes to analyzing diseases and disorders, and mapping out personalized treatment plans for these individuals. It's no secret that our baby-boomer population is going to boost health-care spending dramatically, making Illumina a company that should benefit in a big way, perhaps five to 20 years down the road.
In the meantime, though, Illumina could face a bigger challenge. Like its primary rival Life Technologies, Illumina relies on hospitals, universities, and independent laboratories to buy its genetic analysis tools. Unfortunately, these are the same institutions that rely on government grants to help fund a portion of their research. If you hadn't noticed, with the sequester automatically kicking in, the Federal budget has needed to be reduced by $85 billion. Among the areas that could see these cuts are medical-research programs. So, while growth may continue for Illumina, the magnitude of its growth over the coming two-to-five years may be slower than many investors are accounting for as the U.S. government does its best to pare back its deficit.
At a forward P/E of 41, and at nearly eight times sales, I just don't see where investors have left room for any more value to be squeezed out of this stock, and would suggest you pass on the company here.
Home is where the short-seller is
There's little denying that banking stocks are fickle, and that they often follow the path of the economy. However, I hold pretty true to the old adage on Wall Street that you buy banks when they're notably below book value, and you sell them when they top two times their book value. It's not a perfect science by any means, but it helps to weed out undervalued and overvalued banks from the crowd. Joining Nokia and Illumina in the "sell" column this week is Arkansas Home BancShares .
I will give it to shareholders that they have a lot to be excited about right now, with their company purchasing Liberty BancShares for what amounts to $30 million in cash, and $250 million in Home BancShares' stock. The merger will boost Home's deposit market share and make it the second-largest holding bank based in Arkansas.
With that merger, I'd expect that its price-to-book-value will dip a bit, as well. But, at a current P/B of nearly three, and a forward P/E of 17, I'd have to say that emotions are getting the better of sensible investing lately.
In the second quarter, Home BancShares did deliver great news: It provided an average return on assets of 1.71%, and a 53-basis-point boost in net interest margin that'd make most banks drool with envy. But, at least some of those gains are one time in nature, and relate to additional yield received from FDIC loss-sharing loans. Looking ahead, I see some very difficult year-over-year comparisons for Home BancShares, especially as interest rates rise and consumer loans dry up (mortgage lending income accounted for 16% of all non-interest income), and would suggest investors look for more intriguing values in the banking industry.
This week, it's all about good companies that are being pumped higher by emotional investing rather than disciplined investing. Nokia's smartphone unit sale has spurred buying, but it doesn't have any near-term catalysts left on the horizon. For Illumina, cheaper genomic tests will certainly help boost sales, but, at the same time, a shrinking federal budget will weigh on medical grants and hurt its top-line growth. And finally, for Home BancShares, which has shown that it can grow rapidly through acquisitions, it'll need to demonstrate to shareholders that it can meet or beat its previous quarters on an organic basis if it hopes to maintain its lofty price-to-book ratio.
Have you missed out on the massive gains in bank stocks like Home BancShares over the past few years? There's good news: It's not too late. Bargains of a lifetime are still available, but you need to know where to look. The Motley Fool's new report, "Finding the Next Bank Stock Home Run," will show you how and where to find these deals. It's completely free -- click here to get started.
The article 3 Stocks Near 52-Week Highs Worth Selling originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of, and recommends Nike. It also owns shares of Microsoft and recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.